Promising Emerging Therapies for Multiple Sclerosis

被引：9

作者：

Giovannoni, Gavin ^{[1
]}

机构：

[1] Queen Mary Univ London, Neurosci & Trauma Ctr, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, London E1 2AN, England

来源：

NEUROLOGIC CLINICS | 2011年 / 29卷 / 02期

关键词：

Alemtuzumab; Daclizumab; BG-12; Fumarate; Cladribine; Fingolimod; Laquinimod; Teriflunomide; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRANSCRIPTION FACTOR NRF2; PLACEBO-CONTROLLED TRIAL; CENTRAL-NERVOUS-SYSTEM; CONTROLLED PHASE IIB; BLOOD-BRAIN-BARRIER; AGOUTI RAT MODEL; DOUBLE-BLIND; OXIDATIVE STRESS; T-CELLS;

D O I：

10.1016/j.ncl.2011.01.003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Until recently, interferon beta and glatiramer acetate were the only licensed disease-modifying therapies for relapsing forms of multiple sclerosis. These agents have a modest effect on reducing relapse rates. The licensing of two more effective agents, mitoxantrone and natalizumab, provided alternatives. These agents are associated with potentially life-threatening or serious side effects. In addition, none of these licensed agents has been shown to be effective in primary progressive MS. There is a large unmet need, with several promising new therapies in the pipeline. This article reviews the proposed mechanisms of action of the anticipated treatments, their efficacy, and risks associated with their use.

引用

页码：435 / +

页数：15

共 76 条

[1] Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
Andersen, O
Lycke, J
Tollesson, PO
Svenningsson, A
Runmarker, B
Linde, AS
Astrom, M
Gjorstrup, P
Ekholm, S
[J]. NEUROLOGY, 1996, 47 (04) : 895 - 900
[2] [Anonymous], 2010, MULT SCLER J
[3] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Bar-Or, Amit
Calabresi, Peter A. J.
Arnlod, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd H.
Waubant, Ernmanuelle
Gazda, Suzanne
Fox, Robert J.
Panzara, Michael
Sarkar, Neena
Agarwal, Sunil
Smith, Craig H.
[J]. ANNALS OF NEUROLOGY, 2008, 63 (03) : 395 - 400
[4] Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine
Bartosik-Psujek, H
Belniak, E
Mitosek-Szewczyk, K
Dobosz, B
Stelmasiak, Z
[J]. ACTA NEUROLOGICA SCANDINAVICA, 2004, 109 (06): : 390 - 392
[5] Beutler E, 1996, SEMIN HEMATOL, V33, P45
[6] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
Bielekova, B
Catalfamo, M
Reichert-Scrivner, S
Packer, A
Cerna, M
Waldmann, TA
McFarland, H
Henkart, PA
Martin, R
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) : 5941 - 5946
[7] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
Bielekova, B
Richert, N
Howard, T
Blevins, G
Markovic-Plese, S
McCartin, J
Würfel, J
Ohayon, J
Waidmann, TA
McFarland, HF
Martin, R
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) : 8705 - 8708
[8] CD4+CD25+FOXP3+ regulatory t cells increase De novo in kidney transplant patients after immunodepletion with Campath-1H
Bloom, D. D.
Chang, Z.
Fechner, J. H.
Dar, W.
Polster, S. P.
Pascual, J.
Turka, L. A.
Knechtle, S. J.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (04) : 793 - 802
[9] Rationale and safety of anti-interleukin-23 and anti-interieukin-17A therapy
Bowman, Edward P.
Chackerian, Alissa A.
Cua, Daniel J.
[J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (03) : 245 - 252
[10] FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
Brinkmann, Volker
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (05) : 1173 - 1182

← 1 2 3 4 5 6 7 8 →